Welcome to the Inaugural Hippo Pathway Targeted Drug Development Summit
It has been long understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. With the clear therapeutic potential of this highly attractive and targetable pathway, investment, collaboration, and interest in targeting the Hippo pathway has flooded through biopharma and academia, and a once unexploited pathway is now seeing an abundance of promising therapeutic interventions.
As a once elusive pathway, emerging novel data and literature is forging a wider and more developed mechanistic understanding of this valuable signaling pathway, opening new avenues to evolve the landscape of targetable nodes and therapeutic interventions, from small molecule approaches to novel modalities to target the TEAD transcription complex. The inaugural Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry dedicated forum, focussed on accelerating the mechanistic understanding and potentials of the Hippo signaling pathway to enhance the discovery, translation and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.
Uniting the leading minds of large pharma, biotech and academia, this unrivalled conference will showcase the pioneering discoveries, critical novel findings and promising clinical candidates drugging YAP, TAZ & TEAD transcription factors and other high-value targets within the Hippo pathway, as we dive into:
As this industry continues to unlock critical pieces of the puzzle in the understanding and exploiting this signaling pathway, join leading Translational Scientists, Pharmacologists, and Medicinal Chemists as we unite to learn, debate, discuss, and maximally leverage the therapeutic opportunity of this pathway to address the huge unmet clinical need.